HK1066546A1 - Trifluoromethylpurines as phosphodiesterase 4 inhibitors - Google Patents

Trifluoromethylpurines as phosphodiesterase 4 inhibitors

Info

Publication number
HK1066546A1
HK1066546A1 HK04109532.2A HK04109532A HK1066546A1 HK 1066546 A1 HK1066546 A1 HK 1066546A1 HK 04109532 A HK04109532 A HK 04109532A HK 1066546 A1 HK1066546 A1 HK 1066546A1
Authority
HK
Hong Kong
Prior art keywords
trifluoromethylpurines
phosphodiesterase
inhibitors
Prior art date
Application number
HK04109532.2A
Other languages
English (en)
Inventor
Ruiping Liu
Hans-Jurgen Ernst Hess
Allen Hopper
Yajing Rong
Ashok Tehim
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of HK1066546A1 publication Critical patent/HK1066546A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04109532.2A 2001-02-08 2004-12-01 Trifluoromethylpurines as phosphodiesterase 4 inhibitors HK1066546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26719501P 2001-02-08 2001-02-08
US34482402P 2002-01-07 2002-01-07
PCT/US2002/022509 WO2002098878A1 (en) 2001-02-08 2002-02-08 Trifluoromethylpurines as phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
HK1066546A1 true HK1066546A1 (en) 2005-03-24

Family

ID=26952286

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109532.2A HK1066546A1 (en) 2001-02-08 2004-12-01 Trifluoromethylpurines as phosphodiesterase 4 inhibitors

Country Status (11)

Country Link
US (4) US7342021B2 (xx)
EP (1) EP1383767A1 (xx)
JP (1) JP4443215B2 (xx)
KR (1) KR100863622B1 (xx)
CN (1) CN100439370C (xx)
AU (1) AU2002313673B2 (xx)
BR (1) BR0207302A (xx)
CA (1) CA2438099A1 (xx)
HK (1) HK1066546A1 (xx)
MX (1) MXPA03007134A (xx)
WO (1) WO2002098878A1 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100540046B1 (ko) * 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
WO2004014913A2 (en) * 2002-08-08 2004-02-19 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
EP1551837A1 (en) * 2002-08-08 2005-07-13 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
CN102417508A (zh) * 2003-07-14 2012-04-18 艾尼纳制药公司 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
CN100447143C (zh) * 2003-08-15 2008-12-31 Irm责任有限公司 作为rtk抑制剂的6-取代的苯胺基嘌呤
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
RU2006126791A (ru) * 2003-12-23 2008-01-27 Новартис АГ (CH) Бициклические гетероциклические ингибиторы р-38 киназы
JP2007529464A (ja) 2004-03-16 2007-10-25 グラクソ　グループ　リミテッド ビラゾロ［３，４−ｂ］ピリジン化合物及びＰＤＥ４阻害剤としてのその使用
GB0416699D0 (en) * 2004-07-27 2004-09-01 Prometic Biosciences Ltd Prion protein ligands and methods of use
BRPI0611811A2 (pt) 2005-06-10 2008-12-09 Prometic Biosciences Ltd ligantes de ligaÇço À proteÍna
CA2618636C (en) 2005-08-12 2011-01-18 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands
KR101250820B1 (ko) 2005-08-16 2013-04-04 수벤 라이프 사이언시스 리미티드 개선된 로사르탄 제조 방법
CN101553467B (zh) 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
WO2008131501A2 (en) * 2007-04-27 2008-11-06 Katholieke Universiteit Leuven New anti-viral nucleoside analogs
BRPI0809873A2 (pt) 2007-05-03 2018-11-13 Suven Life Sciences Ltd "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
ES2370680T3 (es) 2007-10-26 2011-12-21 Suven Life Sciences Limited Compuestos de aminoarilsulfonamida y su empleo como ligandos de 5-ht6.
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
WO2010032258A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
WO2010061931A1 (ja) * 2008-11-27 2010-06-03 国立大学法人香川大学 シクロブチルプリン誘導体、血管新生促進剤、管腔形成促進剤、神経細胞成長促進剤および医薬品
ES2552463T3 (es) 2010-01-05 2015-11-30 Suven Life Sciences Limited Compuestos aromáticos de sulfona útiles para el tratamiento de enfermedades del sistema nervioso central
CA2789663C (en) 2010-02-12 2018-10-02 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
MX2017008925A (es) 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
JP2020507611A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 原発性胆汁性胆管炎の治療のための化合物および方法
CN108395432A (zh) * 2018-01-15 2018-08-14 吴江信凯医药科技有限公司 一种2-三氟甲基-6-氨基嘌呤的制备方法
US20210340122A1 (en) * 2018-09-05 2021-11-04 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
RU2746012C2 (ru) * 2019-05-13 2021-04-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917563A (en) 1970-02-17 1975-11-04 Japan Atomic Energy Res Inst Process for the production of high molecular weight polyoxymethylene by the polymerization of tetraoxane
US3919192A (en) * 1972-05-22 1975-11-11 Icn Pharmaceuticals 5-Amino-4-substituted imidazole nucleotides
US3917583A (en) * 1972-08-04 1975-11-04 Icn Pharmaceuticals 2-Substituted cyclic AMP derivatives
AR205247A1 (es) 1973-02-07 1976-04-21 Icn Pharmaceuticals Procedimiento para preparar derivados de amp 2-substituidos
JPS6210085A (ja) 1985-07-05 1987-01-19 Yoshitomi Pharmaceut Ind Ltd トリフルオロメチルプリン誘導体
JPS62240622A (ja) 1986-04-11 1987-10-21 Asahi Glass Co Ltd 抗腫瘍剤
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
JP3086912B2 (ja) 1991-06-20 2000-09-11 工業技術院長 フルオロアルキル基含有プリン誘導体及びその製造方法
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
DE4230755A1 (de) 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (xx) 1992-12-23 1995-11-21 Celltech Ltd
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
US6235736B1 (en) 1997-06-24 2001-05-22 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
KR100540046B1 (ko) 1997-11-12 2006-01-10 미쓰비시 가가꾸 가부시키가이샤 퓨린유도체 및 이를 유효성분으로 함유하는 의약
DE19882892T1 (de) * 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen und Imidazopyridinen
JP4160645B2 (ja) 1997-12-24 2008-10-01 大日本住友製薬株式会社 新規アデニン誘導体及びその医薬用途
JP3542482B2 (ja) 1997-12-25 2004-07-14 日研化学株式会社 ３−アニリノ−２−シクロアルケノン誘導体
JPH11264847A (ja) 1998-03-18 1999-09-28 Advantest Corp スペクトラム・アナライザ
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE19935209A1 (de) 1999-07-27 2001-02-08 Truss Michael C Verwendung von Substanzen, die den intrazellulären Gehalt von zyklischem Adenosinmonophosphat (cAMP) erhöhen oder die Aktivität cAMP-bindender Proteine stimulieren, zur Behandlung von Erkrankungen der Harnblase
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
WO2004014913A2 (en) * 2002-08-08 2004-02-19 Memory Pharmaceuticals Corporation Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
EP1551837A1 (en) * 2002-08-08 2005-07-13 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
US7371737B2 (en) * 2004-09-09 2008-05-13 Solvay Pharmaceuticals, B.V. 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity

Also Published As

Publication number Publication date
CA2438099A1 (en) 2002-12-12
EP1383767A1 (en) 2004-01-28
BR0207302A (pt) 2004-02-10
CN100439370C (zh) 2008-12-03
US20030045533A1 (en) 2003-03-06
US20100010020A1 (en) 2010-01-14
KR20040008127A (ko) 2004-01-28
AU2002313673B2 (en) 2006-09-07
MXPA03007134A (es) 2004-10-15
JP2004528391A (ja) 2004-09-16
KR100863622B1 (ko) 2008-10-15
US20080119495A1 (en) 2008-05-22
US20040242598A1 (en) 2004-12-02
CN1501927A (zh) 2004-06-02
JP4443215B2 (ja) 2010-03-31
US7342021B2 (en) 2008-03-11
WO2002098878A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
PL373301A1 (en) Phosphodiesterase 4 inhibitors
HK1064668A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
PL369728A1 (en) Pyrrolopyrimidines as phosphodiesterase vii inhibitors
HK1080073A1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
SI1671949T1 (sl) Substituirani pridinilamini
TW595857U (en) 091219345
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
PL363391A1 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors
EP1387687A4 (en) NEW USE
PL362643A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
GB0100762D0 (en) Novel use
GB0115181D0 (en) Novel use
PL368050A1 (en) Substituted 4-aminocyclohexanols
EP1364653A4 (en) CASOASE-3 INHIBITORS
GB0202187D0 (en) "Inhibitors"
PL364601A1 (en) Substituted benzo-nitro-heterocycles
ZA200306119B (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors.
GB0101134D0 (en) Inhibitors
GB0128453D0 (en) Inhibitors
GB0101135D0 (en) Inhibitors
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU2002233669A1 (en) Casoase 3 inhibitors
GB0127860D0 (en) Surfaces

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130208